TY  - JOUR
AU  - Haug, Ala Jabri
AU  - Støer, Nathalie
AU  - Langseth, Hilde
AU  - Siafarikas, Franziska
AU  - Botteri, Edoardo
AU  - Fortner, Renée Turzanski
AU  - Lindemann, Kristina
TI  - Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.
JO  - International journal of cancer
VL  - 157
IS  - 2
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2025-00436
SP  - 277-287
PY  - 2025
N1  - Volume157, Issue2, 15 July 2025, Pages 277-287
AB  - While nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to improve survival in certain cancers, data in patients with endometrial cancer (EC) is conflicting. This study investigated use of aspirin and nonaspirin NSAIDs (NA-NSAIDs) and EC-specific-and all-cause death. This nationwide cohort study linked data from the Cancer Registry of Norway with The Norwegian Prescription database. Patients diagnosed with EC from 2004 to 2018 were included. Post-diagnosis exposure to aspirin and NA-NSAIDs was defined as ≥3 consecutive prescriptions ≥30 days after EC diagnosis, with pre-diagnosis use as ≥2 filled prescriptions <6 months prior to diagnosis. Follow-up started 10 months after diagnosis. Hazard ratios for the risk of death were calculated with multivariable Cox-regression models. Our study population included 7751 individuals with EC, 685 (9
KW  - NSAIDS (Other)
KW  - aspirin (Other)
KW  - endometrial cancer (Other)
KW  - survival (Other)
KW  - tertiary prevention (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39992017
DO  - DOI:10.1002/ijc.35363
UR  - https://inrepo02.dkfz.de/record/299476
ER  -